ReviewCurrent obesity reports2025
Mood Disorders, Metabolic Bariatric Surgery, and Weight Loss Pharmacotherapy: a Research Update.
Review in Current obesity reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review explores the intricate and bidirectional relationship between mood disorders and obesity, focusing on the psychiatric implications of metabolic bariatric surgery and weight-loss pharmacotherapy. In particular, the review examines how these interventions impact psychiatric outcomes, identifying both benefits and risks. RECENT
findingsWhile metabolic bariatric surgery and incretin-based therapies improve metabolic health and, in some cases, mental well-being, they may also lead to psychiatric complications. Studies indicate increased risks of mood episodes, self-harm, and altered psychotropic drug metabolism post-surgery. Concerns have also emerged regarding glucagon like peptide-1 (GLP-1) receptor agonists and their potential link to depression and suicidality. Weight-loss interventions require thorough psychiatric assessment prior to treatment, as well as long-term psychiatric monitoring thereafter. Future research should prioritize longitudinal studies with standardized psychiatric assessments to refine risk stratification and optimize clinical outcomes. A multidisciplinary approach integrating endocrinology, psychiatry, and behavioral sciences is essential for improving both physical and mental health outcomes.
Indexed as
Identifiers
41313528What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.